Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV
- Tuberculosis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04166474
- Collaborators
- Infectious Disease Institute, Kampala, Uganda
- Desmond Tutu HIV Centre
- Investigators
- Principal Investigator: Saye Khoo University of Liverpool
Get Well Soon